Targeted biologics have a high efficacy in psoriasis, and the high expression of IL-23A and IL-12B in psoriatic lesions also supports the above hypothesis regarding the pathogenesis of psoriasis [31,32]. This evidence concerns the gene IL12B and psoriasis.